Product Description
The selective Bruton tyrosine kinase (BTK) inhibitor poseltinib has been shown to inhibit the BCR signal transduction pathway and cytokine production in B cells (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34548595/)
Mechanisms of Action: Btk Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Hanmi
Company Location: Western America
Company Founding Year: 1973
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: South Korea
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07114367 |
POTENTIAL-M | P1 |
Recruiting |
Lymphoma, Non-Hodgkin |
2026-12-31 |
35% |
2026-01-31 |
Primary Endpoints|Start Date|Treatments|Trial Status |